Market Spotlight: Irritable Bowel Syndrome (IBS)
Market Spotlight: Irritable Bowel Syndrome (IBS)
$1,318.00
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, licensing and asset acquisition deals, recent events and analyst opinion, a 10-year disease prevalence forecast, and probability of success, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were approximately 546.2 million prevalent cases of irritable bowel syndrome (IBS) in those aged 15 years and over worldwide, and forecasts that number to increase to 604.0 million prevalent cases by 2030.
- The approved drugs in the IBS space target chloride channel 2, calcium channel, sodium-hydrogen exchanger 3, serotonin 5- HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II.
- Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route. The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 13.9%, and the average probability a drug advances from Phase III is 60.5%. Drugs, on average, take 10.3 years from Phase I to approval, compared to 10.1 years in the overall gastroenterology (non inflammatory bowel disease) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 62% of trials in Phase I–II, and only 38% in Phase III–IV.
- The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the IBS space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for IBS, with 28 trials.
- AbbVie leads industry sponsors with the highest overall number of clinical trials for IBS, followed by GSK.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Laxatives
9 Antidiarrheal drugs
9 Antispasmodics
9 Antidepressants
9 Serotonin receptor agonists
10 Chloride channel activators
10 Guanylyl cyclase C agonists
10 Antibiotics
10 Opioid receptors
10 Probiotics
12 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 ORP-101 for IBS (January 4, 2022)
26 GSK3352589 for IBS (June 3, 2021)
29 PROBABILITY OF SUCCESS
30 LICENSING AND ASSET ACQUISITION DEALS
30 France’s Mayoly Spindler Set To Acquire Ipsen’s Consumer Business
31 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
38 BIBLIOGRAPHY
40 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of IBS, 2021–30
20 Figure 2: Overview of pipeline drugs for IBS in the US
20 Figure 3: Pipeline drugs for IBS, by company
21 Figure 4: Pipeline drugs for IBS, by drug type
21 Figure 5: Pipeline drugs for IBS, by classification
26 Figure 6: ORP-101 for IBS (January 4, 2022): Phase II – PREVAIL
28 Figure 7: GSK3352589 for IBS (June 3, 2021): Phase IIa – 201 (Diarrhea-predominant)
29 Figure 8: Probability of success in the gastroenterology (non inflammatory bowel disease)-other pipeline
33 Figure 9: Clinical trials in IBS
33 Figure 10: Top 10 drugs for clinical trials in IBS
34 Figure 11: Top 10 companies for clinical trials in IBS
34 Figure 12: Trial locations in IBS
35 Figure 13: IBS trials status
36 Figure 14: IBS trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of IBS, 2021–30
15 Table 2: Prevalent cases of IBS, by gender, 2021
16 Table 3: Prevalence of IBS, by gender, 2021
18 Table 4: Marketed drugs for IBS
22 Table 5: Pipeline drugs for IBS in the US
25 Table 6: ORP-101 for IBS (January 4, 2022)
27 Table 7: GSK3352589 for IBS (June 3, 2021)
31 Table 8: Historical global sales, by drug ($m), 2017–21
32 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Pulmonary Hypertension 
Sign up to the